Janus Henderson Group PLC Acquires 665,543 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Janus Henderson Group PLC lifted its position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 141.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,135,100 shares of the company's stock after acquiring an additional 665,543 shares during the period. Janus Henderson Group PLC owned 2.52% of Apogee Therapeutics worth $51,455,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jefferies Financial Group Inc. raised its holdings in Apogee Therapeutics by 140.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 887,497 shares of the company's stock worth $40,204,000 after purchasing an additional 518,300 shares in the last quarter. Granahan Investment Management LLC grew its position in shares of Apogee Therapeutics by 1.2% in the 4th quarter. Granahan Investment Management LLC now owns 92,854 shares of the company's stock worth $4,206,000 after buying an additional 1,097 shares during the period. Deutsche Bank AG increased its stake in shares of Apogee Therapeutics by 50.9% in the 4th quarter. Deutsche Bank AG now owns 31,739 shares of the company's stock worth $1,438,000 after acquiring an additional 10,709 shares in the last quarter. Driehaus Capital Management LLC increased its stake in shares of Apogee Therapeutics by 2.8% in the 4th quarter. Driehaus Capital Management LLC now owns 2,605,310 shares of the company's stock worth $118,021,000 after acquiring an additional 71,703 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its position in Apogee Therapeutics by 8.6% during the 4th quarter. Cubist Systematic Strategies LLC now owns 91,213 shares of the company's stock valued at $4,132,000 after acquiring an additional 7,236 shares during the period. Hedge funds and other institutional investors own 79.04% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on APGE. Wedbush reaffirmed an "outperform" rating and set a $90.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Finally, Citigroup began coverage on Apogee Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $95.00 target price on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average target price of $94.60.

Insider Buying and Selling

In other news, insider Carl Dambkowski sold 1,590 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $30.48, for a total value of $48,463.20. Following the transaction, the insider now directly owns 251,033 shares in the company, valued at $7,651,485.84. This trade represents a 0.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael Thomas Henderson sold 10,000 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total value of $301,500.00. Following the sale, the chief executive officer now owns 1,292,987 shares of the company's stock, valued at approximately $38,983,558.05. This trade represents a 0.77% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,175 shares of company stock worth $587,191. 42.77% of the stock is owned by corporate insiders.

Apogee Therapeutics Price Performance

NASDAQ APGE traded down $0.87 during mid-day trading on Monday, reaching $39.75. The stock had a trading volume of 187,140 shares, compared to its average volume of 521,968. Apogee Therapeutics, Inc. has a 1 year low of $26.20 and a 1 year high of $63.50. The stock has a market cap of $1.83 billion, a PE ratio of -16.54 and a beta of 1.70. The company has a fifty day moving average price of $36.66 and a 200 day moving average price of $41.02.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.95) EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $0.24. As a group, equities research analysts expect that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.